Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - Sio Gene Therapies Inc. | axovantexhibit311.htm |
| 10-K - 10-K - Sio Gene Therapies Inc. | axovant3312010k.htm |
| EX-32.2 - EXHIBIT 32.2 - Sio Gene Therapies Inc. | axovantexhibit322.htm |
| EX-32.1 - EXHIBIT 32.1 - Sio Gene Therapies Inc. | axovantexhibit321.htm |
| EX-31.2 - EXHIBIT 31.2 - Sio Gene Therapies Inc. | axovantexhibit312.htm |
| EX-21.1 - EXHIBIT 21.1 - Sio Gene Therapies Inc. | axovantexhibit211.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements of Axovant Gene Therapies Ltd.:
(1) Registration Statement (Form S-8 No. 333-206300) pertaining to the 2015 Equity Incentive Plan;
(2) Registration Statement (Form S-8 No. 333-215386) pertaining to the 2015 Equity Incentive Plan;
(3) Registration Statement (Form S-3 No. 333-215387);
(4) Registration Statement (Form S-8 No. 333-220089) pertaining to the Amended and Restated 2015 Equity
Incentive Plan;
(5) Registration Statement (Form S-8 No. 333-226877) pertaining to the Amended and Restated 2015 Equity Incentive Plan; and
(6) Registration Statement (Form S-3 No. 333-235889);
of our report dated June 9, 2020, with respect to the consolidated financial statements of Axovant Gene Therapies Ltd. included in this Annual Report (Form 10-K) of Axovant Gene Therapies Ltd. for the year ended March 31, 2020.
/s/ Ernst & Young LLP
Iselin, New Jersey
June 9, 2020
1